Last reviewed · How we verify
YM060
YM060 is a kappa opioid receptor antagonist Small molecule drug developed by Astellas Pharma Inc. It is currently in Phase 3 development for Chronic pain. Also known as: ramosetron, Irribow, ramosetron, Irribow, Ramosetron.
YM060 is a selective and potent kappa opioid receptor antagonist.
YM060, also known as Ramosetron Hydrochloride, is a small molecule serotonin 3 (5-HT3) receptor antagonist. It has been studied in clinical trials for various conditions, including Irritable Bowel Syndrome, postoperative nausea and vomiting, and others.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | YM060 |
|---|---|
| Also known as | ramosetron, Irribow, ramosetron, Irribow, Ramosetron, ramosetron, |
| Sponsor | Astellas Pharma Inc |
| Drug class | kappa opioid receptor antagonist |
| Target | kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Mechanism of action
YM060 works by blocking the kappa opioid receptor, which is involved in pain modulation and other physiological processes. This action is thought to contribute to its analgesic effects. However, the exact mechanisms underlying its therapeutic effects are not fully understood.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
Key clinical trials
- Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (NA)
- Special Drug Use Surveillance of Irribow in Female Patients
- The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting (NA)
- Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery (NA)
- The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence (PHASE2, PHASE3)
- 5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS) (NA)
- The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in High Risk Patients
- Ramosetron on Late PONV (Postoperative Nausea and Vomiting) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YM060 CI brief — competitive landscape report
- YM060 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about YM060
What is YM060?
How does YM060 work?
What is YM060 used for?
Who makes YM060?
Is YM060 also known as anything else?
What drug class is YM060 in?
What development phase is YM060 in?
What are the side effects of YM060?
What does YM060 target?
Related
- Drug class: All kappa opioid receptor antagonist drugs
- Target: All drugs targeting kappa opioid receptor
- Manufacturer: Astellas Pharma Inc — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Chronic pain
- Also known as: ramosetron, Irribow, ramosetron, Irribow, Ramosetron, ramosetron,
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing